Alkem Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Alkem Laboratories ha aumentado sus beneficios a una tasa media anual de 7.6%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 11.4% al año. La rentabilidad financiera de Alkem Laboratories es de 15.4%, y sus márgenes netos son de 12.5%.

Información clave

7.6%

Tasa de crecimiento de los beneficios

7.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	17.5%
Tasa de crecimiento de los ingresos	11.4%
Rentabilidad financiera	15.4%
Margen neto	12.5%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17

These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

Sep 20

Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Jul 27

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 13

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Jun 11

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

May 23

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Mar 06

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Feb 21

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Feb 08

Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?

Jan 09

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Nov 30

Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly

Nov 17

I Built A List Of Growing Companies And Alkem Laboratories (NSE:ALKEM) Made The Cut

Sep 07

Here's Why Alkem Laboratories Limited's (NSE:ALKEM) CEO May Deserve A Raise

Aug 20

Alkem Laboratories (NSE:ALKEM) Is Increasing Its Dividend To ₹5.00

Aug 03

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Jul 19

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Jul 01

Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?

May 25

What Kind Of Investors Own Most Of Alkem Laboratories Limited (NSE:ALKEM)?

Mar 17

Why Dividend Hunters Love Alkem Laboratories Limited (NSE:ALKEM)

Mar 04

Alkem Laboratories Limited (NSE:ALKEM) Insiders Have Been Selling

Feb 19

Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?

Feb 07

Alkem Laboratories (NSE:ALKEM) Could Be A Buy For Its Upcoming Dividend

Feb 07

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Alkem Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NSEI:ALKEM Ingresos, gastos y beneficios (INR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	126,344	15,732	30,394	0
30 Sep 23	123,514	14,329	29,926	0
30 Jun 23	119,906	11,433	30,081	0
31 Mar 23	115,993	9,842	29,726	0
31 Dec 22	111,805	10,208	27,081	0
30 Sep 22	107,586	10,917	26,536	0
30 Jun 22	104,792	13,051	25,772	0
31 Mar 22	106,342	16,456	25,769	0
31 Dec 21	103,425	17,780	22,660	0
30 Sep 21	100,416	17,033	22,048	0
30 Jun 21	96,044	16,311	21,183	0
31 Mar 21	88,650	15,850	19,807	0
31 Dec 20	87,218	15,338	21,217	0
30 Sep 20	85,971	14,648	21,076	0
30 Jun 20	84,984	13,636	20,892	0
31 Mar 20	83,444	11,271	20,853	0
31 Dec 19	81,484	11,057	20,347	0
30 Sep 19	78,929	9,262	19,855	0
30 Jun 19	75,478	8,098	19,237	0
31 Mar 19	73,572	7,605	18,728	0
31 Dec 18	70,157	6,602	17,762	0
30 Sep 18	68,318	6,293	17,412	0
30 Jun 18	67,788	6,955	17,212	0
31 Mar 18	63,918	6,309	16,555	0
31 Dec 17	60,044	7,009	15,102	0
30 Sep 17	57,285	7,626	14,699	0
30 Jun 17	55,019	7,248	14,245	0
31 Mar 17	56,875	8,920	13,910	0
31 Dec 16	56,933	7,732	13,497	0
30 Sep 16	54,992	7,267	12,977	0
30 Jun 16	52,419	7,108	9,430	0
31 Mar 16	49,248	7,416	11,699	0
31 Dec 15	47,975	8,189	15,267	220
30 Sep 15	44,556	7,227	15,252	291
30 Jun 15	40,459	5,781	11,940	150
31 Mar 15	37,434	3,916	9,032	0
31 Mar 14	31,191	4,353	10,466	210

Ingresos de calidad: ALKEM tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (12.5%) de ALKEM son superiores a los del año pasado (9.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de ALKEM han crecido un 7.6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de ALKEM en el último año (54.1%) supera su media de 5 años (7.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ALKEM en el último año (54.1%) superó al de la industria Pharmaceuticals 23.8%.

Alkem Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Announces CFO Changes

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa

Alkem Laboratories Limited Appoints Srinivas Singh as (Executive) Additional Director and Whole Time Director

Alkem Laboratories Limited Announces Retirement of Balmiki Prasad Singh as Executive Director

Price target decreased to ₹3,357

Alkem Laboratories Limited Appoints Sujjain Talwar as an Additional Director, Designated as an Independent Director on the Board of Directors

Upcoming dividend of ₹4.00 per share

Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Alkem Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories Limited Announces Resignation of Ranjal Laxmana Shenoy as Non- Executive Independent Director

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Price target decreased to ₹3,624

Alkem Laboratories Limited Proposes Final Dividend for Financial Year Ended 31 March, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹90m worth of stock

Executive Director recently bought ₹16m worth of stock

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

The Pharma Network LLC acquired 100% shares of S&b Pharma, Inc from Alkem Laboratories Limited (BSE:539523).

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?

Desglose de ingresos y gastos
Beta